Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 183 | 2024 | 17347 | 4.190 |
Why?
|
HIV-1 | 97 | 2024 | 6851 | 3.410 |
Why?
|
Anti-HIV Agents | 75 | 2024 | 4526 | 2.860 |
Why?
|
Viral Load | 71 | 2024 | 3328 | 2.540 |
Why?
|
CD4 Lymphocyte Count | 69 | 2022 | 2569 | 2.010 |
Why?
|
Antiretroviral Therapy, Highly Active | 43 | 2022 | 1895 | 1.940 |
Why?
|
RNA, Viral | 59 | 2024 | 2839 | 1.760 |
Why?
|
Viremia | 22 | 2024 | 707 | 1.640 |
Why?
|
Anti-Retroviral Agents | 34 | 2024 | 1784 | 1.630 |
Why?
|
CD4-Positive T-Lymphocytes | 45 | 2024 | 4372 | 1.540 |
Why?
|
CD8-Positive T-Lymphocytes | 28 | 2024 | 4574 | 1.510 |
Why?
|
Lymphocyte Activation | 21 | 2023 | 5478 | 1.230 |
Why?
|
HIV | 18 | 2023 | 1581 | 1.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 11 | 2022 | 2196 | 1.060 |
Why?
|
Virus Latency | 11 | 2023 | 354 | 0.890 |
Why?
|
DNA, Viral | 14 | 2024 | 2195 | 0.790 |
Why?
|
Drug Resistance, Viral | 14 | 2023 | 862 | 0.780 |
Why?
|
Proviruses | 8 | 2024 | 313 | 0.740 |
Why?
|
HIV Seropositivity | 4 | 2022 | 957 | 0.670 |
Why?
|
Reverse Transcriptase Inhibitors | 10 | 2006 | 621 | 0.590 |
Why?
|
Infectious Disease Transmission, Vertical | 10 | 2016 | 1351 | 0.540 |
Why?
|
Data Interpretation, Statistical | 3 | 2015 | 2691 | 0.510 |
Why?
|
Models, Statistical | 6 | 2024 | 5081 | 0.480 |
Why?
|
Vitamin B 12 | 5 | 2019 | 524 | 0.480 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 39 | 0.470 |
Why?
|
Dietary Supplements | 12 | 2019 | 3410 | 0.430 |
Why?
|
Vitamins | 9 | 2014 | 1634 | 0.430 |
Why?
|
Sarcoma, Kaposi | 3 | 2022 | 374 | 0.420 |
Why?
|
Anthropometry | 5 | 2017 | 1338 | 0.420 |
Why?
|
Research Design | 5 | 2014 | 6180 | 0.400 |
Why?
|
Cytomegalovirus Infections | 5 | 2024 | 828 | 0.400 |
Why?
|
Adult | 128 | 2024 | 221119 | 0.390 |
Why?
|
Benzoxazines | 7 | 2014 | 316 | 0.380 |
Why?
|
Lymphocyte Subsets | 1 | 2012 | 312 | 0.360 |
Why?
|
Humans | 211 | 2024 | 761208 | 0.360 |
Why?
|
Bacterial Translocation | 3 | 2015 | 73 | 0.360 |
Why?
|
Withholding Treatment | 5 | 2021 | 616 | 0.360 |
Why?
|
Male | 143 | 2024 | 360693 | 0.360 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1256 | 0.350 |
Why?
|
Female | 142 | 2024 | 392544 | 0.330 |
Why?
|
Vitamin B 12 Deficiency | 3 | 2016 | 118 | 0.320 |
Why?
|
Body Height | 2 | 2014 | 1566 | 0.320 |
Why?
|
Virus Replication | 12 | 2019 | 2426 | 0.310 |
Why?
|
Pregnancy Complications, Infectious | 9 | 2016 | 2150 | 0.290 |
Why?
|
Lamivudine | 5 | 2016 | 366 | 0.290 |
Why?
|
Maternal Nutritional Physiological Phenomena | 4 | 2019 | 390 | 0.280 |
Why?
|
Middle Aged | 88 | 2024 | 220853 | 0.280 |
Why?
|
Peripheral Nervous System Diseases | 4 | 2015 | 709 | 0.280 |
Why?
|
CD4-CD8 Ratio | 4 | 2022 | 114 | 0.280 |
Why?
|
Tanzania | 16 | 2016 | 1390 | 0.270 |
Why?
|
Plasma | 3 | 2021 | 586 | 0.270 |
Why?
|
T-Lymphocytes | 11 | 2021 | 10203 | 0.270 |
Why?
|
Interleukin-2 | 2 | 2011 | 1891 | 0.270 |
Why?
|
Causality | 2 | 2024 | 1244 | 0.270 |
Why?
|
Oxazines | 4 | 2006 | 349 | 0.260 |
Why?
|
Inflammation | 12 | 2023 | 10759 | 0.260 |
Why?
|
Adjuvants, Immunologic | 2 | 2011 | 988 | 0.260 |
Why?
|
Didanosine | 4 | 2007 | 151 | 0.260 |
Why?
|
HLA-C Antigens | 3 | 2015 | 141 | 0.250 |
Why?
|
Alkynes | 7 | 2014 | 320 | 0.250 |
Why?
|
Killer Cells, Natural | 4 | 2024 | 2194 | 0.240 |
Why?
|
HIV Envelope Protein gp41 | 4 | 2013 | 303 | 0.240 |
Why?
|
Cyclopropanes | 7 | 2014 | 432 | 0.240 |
Why?
|
Ritonavir | 3 | 2014 | 329 | 0.240 |
Why?
|
Dideoxynucleosides | 2 | 2018 | 135 | 0.240 |
Why?
|
Valproic Acid | 4 | 2010 | 443 | 0.230 |
Why?
|
Anus Neoplasms | 2 | 2022 | 330 | 0.230 |
Why?
|
Drug Therapy, Combination | 19 | 2019 | 6304 | 0.230 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2004 | 25 | 0.230 |
Why?
|
Leukocytes, Mononuclear | 11 | 2020 | 1838 | 0.220 |
Why?
|
AIDS Vaccines | 5 | 2010 | 891 | 0.220 |
Why?
|
HLA-DR Antigens | 3 | 2014 | 606 | 0.220 |
Why?
|
Anemia | 4 | 2022 | 1504 | 0.220 |
Why?
|
Likelihood Functions | 4 | 2024 | 991 | 0.220 |
Why?
|
Hepatitis C | 5 | 2022 | 1579 | 0.220 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2016 | 662 | 0.220 |
Why?
|
T-Lymphocyte Subsets | 4 | 2019 | 1803 | 0.210 |
Why?
|
Cytomegalovirus | 3 | 2023 | 750 | 0.210 |
Why?
|
North America | 9 | 2022 | 1284 | 0.210 |
Why?
|
Anemia, Iron-Deficiency | 3 | 2012 | 369 | 0.210 |
Why?
|
Histone Deacetylase Inhibitors | 6 | 2022 | 774 | 0.200 |
Why?
|
Pyrrolidinones | 3 | 2012 | 116 | 0.200 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2024 | 330 | 0.200 |
Why?
|
AIDS Dementia Complex | 2 | 2017 | 153 | 0.190 |
Why?
|
Micronutrients | 4 | 2016 | 381 | 0.190 |
Why?
|
Cohort Studies | 31 | 2023 | 41496 | 0.190 |
Why?
|
Treatment Outcome | 31 | 2022 | 64681 | 0.190 |
Why?
|
Hydroxamic Acids | 2 | 2014 | 479 | 0.190 |
Why?
|
Breast Feeding | 5 | 2016 | 1356 | 0.180 |
Why?
|
Biomedical Research | 2 | 2014 | 3434 | 0.180 |
Why?
|
Drug Resistance, Multiple, Viral | 2 | 2011 | 52 | 0.180 |
Why?
|
Canada | 8 | 2023 | 2125 | 0.180 |
Why?
|
Cholesterol, LDL | 4 | 2022 | 2380 | 0.180 |
Why?
|
RNA | 4 | 2023 | 2709 | 0.180 |
Why?
|
Hydroxyurea | 3 | 2007 | 284 | 0.170 |
Why?
|
HIV Antigens | 1 | 2021 | 325 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 3245 | 0.170 |
Why?
|
Cognition | 5 | 2019 | 6988 | 0.170 |
Why?
|
Oropharynx | 1 | 2020 | 137 | 0.170 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 75 | 0.170 |
Why?
|
Sputum | 2 | 2020 | 505 | 0.170 |
Why?
|
Virus Shedding | 3 | 2023 | 109 | 0.160 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2012 | 830 | 0.160 |
Why?
|
Child Development | 4 | 2019 | 2302 | 0.160 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 206 | 0.160 |
Why?
|
Milk, Human | 2 | 2016 | 486 | 0.160 |
Why?
|
Young Adult | 33 | 2021 | 59221 | 0.160 |
Why?
|
Disease Reservoirs | 3 | 2018 | 121 | 0.150 |
Why?
|
Herpesvirus 3, Human | 1 | 2019 | 159 | 0.150 |
Why?
|
Clinical Trials as Topic | 5 | 2016 | 8003 | 0.150 |
Why?
|
Vitamin A | 3 | 2010 | 612 | 0.150 |
Why?
|
HIV Long-Term Survivors | 1 | 2018 | 121 | 0.150 |
Why?
|
Longitudinal Studies | 14 | 2024 | 14610 | 0.140 |
Why?
|
Nasopharynx | 1 | 2020 | 400 | 0.140 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 147 | 0.140 |
Why?
|
Sirolimus | 1 | 2024 | 1540 | 0.140 |
Why?
|
Double-Blind Method | 14 | 2022 | 12341 | 0.140 |
Why?
|
Nutritional Status | 3 | 2016 | 1597 | 0.140 |
Why?
|
Herpes Zoster | 1 | 2019 | 253 | 0.140 |
Why?
|
India | 7 | 2019 | 2287 | 0.140 |
Why?
|
HIV Reverse Transcriptase | 4 | 2005 | 212 | 0.140 |
Why?
|
Fetal Development | 2 | 2019 | 768 | 0.130 |
Why?
|
Anticholesteremic Agents | 1 | 2022 | 968 | 0.130 |
Why?
|
Prenatal Care | 3 | 2019 | 1141 | 0.130 |
Why?
|
Peptide Fragments | 5 | 2013 | 5103 | 0.120 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2016 | 155 | 0.120 |
Why?
|
HLA-A Antigens | 1 | 2015 | 223 | 0.120 |
Why?
|
Immunotherapy | 1 | 2011 | 4642 | 0.120 |
Why?
|
Drug Administration Schedule | 8 | 2019 | 4851 | 0.120 |
Why?
|
Rifamycins | 1 | 2014 | 26 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1372 | 0.120 |
Why?
|
Infant, Low Birth Weight | 2 | 2017 | 869 | 0.120 |
Why?
|
Contraceptive Agents, Female | 1 | 2016 | 118 | 0.120 |
Why?
|
Infant | 16 | 2022 | 36169 | 0.120 |
Why?
|
Hair | 1 | 2018 | 498 | 0.120 |
Why?
|
Blood | 2 | 2014 | 596 | 0.120 |
Why?
|
Membrane Glycoproteins | 3 | 2014 | 3696 | 0.120 |
Why?
|
Tuberculosis | 3 | 2011 | 2016 | 0.120 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1076 | 0.120 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 2 | 2011 | 29 | 0.120 |
Why?
|
Pregnancy | 20 | 2019 | 29893 | 0.120 |
Why?
|
Prospective Studies | 24 | 2020 | 54435 | 0.120 |
Why?
|
HIV Antibodies | 2 | 2019 | 1301 | 0.110 |
Why?
|
Risk Factors | 26 | 2022 | 74239 | 0.110 |
Why?
|
HLA-B Antigens | 1 | 2015 | 317 | 0.110 |
Why?
|
Body Fluid Compartments | 1 | 2014 | 50 | 0.110 |
Why?
|
Myocardial Infarction | 4 | 2022 | 11476 | 0.110 |
Why?
|
Sex Factors | 5 | 2018 | 10553 | 0.110 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2013 | 34 | 0.110 |
Why?
|
International Educational Exchange | 1 | 2014 | 49 | 0.110 |
Why?
|
Mutation | 8 | 2023 | 30002 | 0.110 |
Why?
|
Interferon-gamma | 5 | 2021 | 3155 | 0.110 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 614 | 0.110 |
Why?
|
Polyamines | 1 | 2014 | 133 | 0.110 |
Why?
|
Sensitivity and Specificity | 5 | 2024 | 14675 | 0.110 |
Why?
|
Lymphocyte Count | 6 | 2019 | 781 | 0.110 |
Why?
|
Computer Simulation | 3 | 2024 | 6224 | 0.110 |
Why?
|
Receptors, CCR5 | 1 | 2015 | 487 | 0.110 |
Why?
|
HIV Protease Inhibitors | 4 | 2020 | 432 | 0.110 |
Why?
|
Education, Graduate | 1 | 2014 | 75 | 0.110 |
Why?
|
Infant Mortality | 4 | 2012 | 752 | 0.110 |
Why?
|
Prevalence | 13 | 2022 | 15721 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10218 | 0.110 |
Why?
|
Chemokine CCL2 | 1 | 2015 | 602 | 0.110 |
Why?
|
Monitoring, Immunologic | 1 | 2013 | 99 | 0.100 |
Why?
|
Postpartum Period | 1 | 2019 | 1178 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2018 | 874 | 0.100 |
Why?
|
Prenatal Nutritional Physiological Phenomena | 1 | 2014 | 160 | 0.100 |
Why?
|
Thromboplastin | 1 | 2014 | 286 | 0.100 |
Why?
|
Nutritional Sciences | 1 | 2014 | 144 | 0.100 |
Why?
|
Pregnancy Trimester, First | 2 | 2014 | 908 | 0.100 |
Why?
|
Immunity, Cellular | 2 | 2016 | 1553 | 0.100 |
Why?
|
Age Factors | 5 | 2013 | 18384 | 0.100 |
Why?
|
Patient Dropouts | 1 | 2014 | 411 | 0.100 |
Why?
|
Phylogeny | 2 | 2023 | 2809 | 0.100 |
Why?
|
Infant, Newborn | 12 | 2017 | 26199 | 0.100 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2023 | 1783 | 0.100 |
Why?
|
Aging | 4 | 2022 | 8702 | 0.100 |
Why?
|
Case-Control Studies | 11 | 2020 | 22174 | 0.100 |
Why?
|
Receptors, Immunologic | 2 | 2024 | 1408 | 0.100 |
Why?
|
Lactation | 1 | 2014 | 397 | 0.100 |
Why?
|
Diarrhea | 2 | 2016 | 1316 | 0.100 |
Why?
|
Interferon-alpha | 2 | 2013 | 907 | 0.090 |
Why?
|
Apolipoproteins | 1 | 2013 | 327 | 0.090 |
Why?
|
Iron, Dietary | 1 | 2012 | 148 | 0.090 |
Why?
|
beta Carotene | 2 | 2010 | 523 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2017 | 2254 | 0.090 |
Why?
|
Growth | 1 | 2013 | 365 | 0.090 |
Why?
|
Phosphorus | 1 | 2012 | 332 | 0.090 |
Why?
|
Lipoproteins, LDL | 1 | 2014 | 643 | 0.090 |
Why?
|
Nervous System | 1 | 2014 | 545 | 0.090 |
Why?
|
Adolescent | 22 | 2019 | 88298 | 0.090 |
Why?
|
Dendritic Cells | 3 | 2013 | 2726 | 0.090 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1069 | 0.090 |
Why?
|
Caspase 8 | 1 | 2010 | 190 | 0.090 |
Why?
|
Cytokines | 4 | 2018 | 7386 | 0.090 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2019 | 2517 | 0.090 |
Why?
|
Incidence | 11 | 2019 | 21365 | 0.080 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 351 | 0.080 |
Why?
|
Canarypox virus | 1 | 2009 | 10 | 0.080 |
Why?
|
Patient Readmission | 1 | 2023 | 3265 | 0.080 |
Why?
|
Aged | 24 | 2022 | 169288 | 0.080 |
Why?
|
Calcium, Dietary | 1 | 2012 | 529 | 0.080 |
Why?
|
Enzyme Inhibitors | 4 | 2010 | 3702 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2013 | 675 | 0.080 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 12474 | 0.080 |
Why?
|
Antiviral Agents | 3 | 2023 | 3048 | 0.080 |
Why?
|
Vaccines, DNA | 1 | 2010 | 280 | 0.080 |
Why?
|
Antirheumatic Agents | 1 | 2018 | 1369 | 0.080 |
Why?
|
Deoxyadenine Nucleotides | 1 | 2007 | 14 | 0.080 |
Why?
|
Vaccination | 3 | 2011 | 3369 | 0.080 |
Why?
|
Toll-Like Receptor 7 | 1 | 2009 | 165 | 0.080 |
Why?
|
Growth Disorders | 1 | 2013 | 634 | 0.080 |
Why?
|
Models, Theoretical | 2 | 2017 | 3571 | 0.070 |
Why?
|
Blood Coagulation | 1 | 2014 | 1156 | 0.070 |
Why?
|
Cardiovascular Agents | 1 | 2014 | 842 | 0.070 |
Why?
|
Follow-Up Studies | 10 | 2019 | 39126 | 0.070 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2009 | 138 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2019 | 3092 | 0.070 |
Why?
|
Interleukin-7 | 2 | 2005 | 143 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 2 | 2003 | 788 | 0.070 |
Why?
|
Oligopeptides | 1 | 2012 | 1179 | 0.070 |
Why?
|
Vitamin B Complex | 1 | 2009 | 299 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 447 | 0.070 |
Why?
|
Life Expectancy | 1 | 2013 | 1242 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2014 | 4340 | 0.070 |
Why?
|
Diet | 3 | 2013 | 8048 | 0.070 |
Why?
|
Body Mass Index | 2 | 2016 | 12952 | 0.070 |
Why?
|
United States | 15 | 2023 | 72339 | 0.070 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 465 | 0.070 |
Why?
|
Proteinuria | 1 | 2009 | 605 | 0.060 |
Why?
|
Lectins, C-Type | 2 | 2024 | 585 | 0.060 |
Why?
|
Time Factors | 9 | 2021 | 39957 | 0.060 |
Why?
|
Evolution, Molecular | 1 | 2014 | 1882 | 0.060 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7804 | 0.060 |
Why?
|
Lipids | 1 | 2016 | 3331 | 0.060 |
Why?
|
Infection Control | 1 | 2012 | 983 | 0.060 |
Why?
|
Zidovudine | 2 | 2004 | 624 | 0.060 |
Why?
|
Gene Expression Regulation | 2 | 2013 | 11856 | 0.060 |
Why?
|
Immunologic Memory | 3 | 2024 | 1361 | 0.060 |
Why?
|
Human Growth Hormone | 1 | 2010 | 642 | 0.060 |
Why?
|
Clinical Protocols | 1 | 2011 | 1436 | 0.060 |
Why?
|
Malaria | 2 | 2012 | 1225 | 0.060 |
Why?
|
Thymus Gland | 2 | 2010 | 1243 | 0.060 |
Why?
|
Nylons | 1 | 2004 | 46 | 0.060 |
Why?
|
Polymerase Chain Reaction | 4 | 2017 | 6067 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13367 | 0.060 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 109 | 0.060 |
Why?
|
Cytosol | 1 | 2007 | 883 | 0.060 |
Why?
|
Indinavir | 1 | 2004 | 73 | 0.060 |
Why?
|
Genes, MDR | 1 | 2003 | 36 | 0.060 |
Why?
|
Population Surveillance | 3 | 2021 | 2598 | 0.060 |
Why?
|
Flow Cytometry | 5 | 2019 | 5871 | 0.060 |
Why?
|
Hemoglobins | 4 | 2013 | 1525 | 0.060 |
Why?
|
Glomerular Filtration Rate | 2 | 2013 | 2182 | 0.060 |
Why?
|
Iron | 1 | 2012 | 1790 | 0.050 |
Why?
|
Treatment Failure | 4 | 2012 | 2643 | 0.050 |
Why?
|
Central Nervous System | 1 | 2011 | 1333 | 0.050 |
Why?
|
Placebos | 2 | 2021 | 1666 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2007 | 2359 | 0.050 |
Why?
|
HIV Long Terminal Repeat | 3 | 2012 | 85 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2012 | 2567 | 0.050 |
Why?
|
Risk Assessment | 6 | 2018 | 24021 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2010 | 6504 | 0.050 |
Why?
|
Disease Progression | 6 | 2019 | 13511 | 0.050 |
Why?
|
STAT5 Transcription Factor | 1 | 2023 | 266 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
Survival Analysis | 5 | 2016 | 10088 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Genotype | 6 | 2015 | 12985 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2007 | 3976 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2022 | 57 | 0.050 |
Why?
|
Comorbidity | 4 | 2021 | 10516 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2478 | 0.050 |
Why?
|
Neuropsychological Tests | 3 | 2017 | 7046 | 0.050 |
Why?
|
Prednisolone | 1 | 2003 | 324 | 0.050 |
Why?
|
Predictive Value of Tests | 8 | 2013 | 15308 | 0.050 |
Why?
|
Patient Compliance | 2 | 2009 | 2688 | 0.050 |
Why?
|
Research Subjects | 1 | 2004 | 249 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2022 | 2082 | 0.050 |
Why?
|
Interleukin-12 | 1 | 2004 | 578 | 0.050 |
Why?
|
Homocysteine | 2 | 2016 | 637 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10707 | 0.050 |
Why?
|
Malnutrition | 1 | 2007 | 622 | 0.050 |
Why?
|
Receptors, IgG | 1 | 2024 | 558 | 0.050 |
Why?
|
Cells, Cultured | 6 | 2020 | 18926 | 0.050 |
Why?
|
Acute Disease | 4 | 2015 | 7226 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2023 | 11101 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2019 | 0.050 |
Why?
|
Pyridines | 1 | 2012 | 2872 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13632 | 0.040 |
Why?
|
Heterochromatin | 1 | 2023 | 291 | 0.040 |
Why?
|
Antigens, CD | 1 | 2011 | 4009 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9187 | 0.040 |
Why?
|
Regression Analysis | 2 | 2007 | 6345 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2017 | 12159 | 0.040 |
Why?
|
Vomiting | 2 | 2014 | 650 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2024 | 610 | 0.040 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 26071 | 0.040 |
Why?
|
Hypertension | 2 | 2017 | 8536 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3089 | 0.040 |
Why?
|
Serologic Tests | 1 | 2021 | 381 | 0.040 |
Why?
|
DNA | 2 | 2024 | 7189 | 0.040 |
Why?
|
Granzymes | 1 | 2021 | 276 | 0.040 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 84 | 0.040 |
Why?
|
Stroke | 2 | 2018 | 9721 | 0.040 |
Why?
|
K562 Cells | 2 | 2011 | 640 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2004 | 976 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2009 | 2640 | 0.040 |
Why?
|
Defective Viruses | 1 | 2018 | 89 | 0.040 |
Why?
|
ROC Curve | 2 | 2003 | 3584 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15520 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12939 | 0.040 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 582 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2949 | 0.040 |
Why?
|
Tamoxifen | 1 | 2022 | 965 | 0.040 |
Why?
|
Mothers | 3 | 2016 | 2193 | 0.040 |
Why?
|
HIV Core Protein p24 | 2 | 2010 | 244 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13385 | 0.040 |
Why?
|
Nonlinear Dynamics | 1 | 2020 | 492 | 0.040 |
Why?
|
Immune Evasion | 1 | 2021 | 364 | 0.040 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2017 | 124 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2008 | 2092 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 17897 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2009 | 3313 | 0.030 |
Why?
|
Lipopolysaccharides | 2 | 2014 | 2199 | 0.030 |
Why?
|
Postnatal Care | 1 | 2019 | 260 | 0.030 |
Why?
|
Endpoint Determination | 2 | 2011 | 590 | 0.030 |
Why?
|
Phenotype | 7 | 2013 | 16575 | 0.030 |
Why?
|
Cell Cycle | 1 | 2024 | 2925 | 0.030 |
Why?
|
Alleles | 3 | 2015 | 6857 | 0.030 |
Why?
|
Drug Hypersensitivity | 1 | 2005 | 918 | 0.030 |
Why?
|
Odds Ratio | 3 | 2013 | 9652 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7407 | 0.030 |
Why?
|
Birth Weight | 2 | 2017 | 2104 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 965 | 0.030 |
Why?
|
Folic Acid | 2 | 2013 | 1323 | 0.030 |
Why?
|
DNA, Circular | 1 | 2015 | 96 | 0.030 |
Why?
|
Hepacivirus | 1 | 2022 | 1330 | 0.030 |
Why?
|
Prognosis | 2 | 2013 | 29687 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5869 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3264 | 0.030 |
Why?
|
Thailand | 1 | 2015 | 287 | 0.030 |
Why?
|
Amino Acid Substitution | 2 | 2012 | 1737 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 22140 | 0.030 |
Why?
|
Hip | 2 | 2009 | 255 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2014 | 76 | 0.030 |
Why?
|
Cell Proliferation | 4 | 2011 | 10422 | 0.030 |
Why?
|
Lymphocytes | 1 | 2002 | 2603 | 0.030 |
Why?
|
Genome, Viral | 1 | 2018 | 665 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2016 | 555 | 0.030 |
Why?
|
Immunophenotyping | 2 | 2012 | 1867 | 0.030 |
Why?
|
Retrospective Studies | 6 | 2014 | 80674 | 0.030 |
Why?
|
Depression | 1 | 2014 | 8132 | 0.030 |
Why?
|
Antimalarials | 2 | 2012 | 907 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2019 | 858 | 0.030 |
Why?
|
Codon | 2 | 2006 | 597 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2015 | 716 | 0.030 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2016 | 504 | 0.030 |
Why?
|
Avitaminosis | 1 | 2013 | 35 | 0.030 |
Why?
|
Chronic Disease | 4 | 2015 | 9319 | 0.030 |
Why?
|
Methylmalonic Acid | 1 | 2013 | 49 | 0.030 |
Why?
|
Survivors | 1 | 2023 | 2369 | 0.030 |
Why?
|
Gestational Age | 2 | 2014 | 3580 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2015 | 1624 | 0.030 |
Why?
|
Language Development | 1 | 2014 | 183 | 0.030 |
Why?
|
Algorithms | 2 | 2020 | 14025 | 0.030 |
Why?
|
Anemia, Hypochromic | 1 | 2012 | 63 | 0.030 |
Why?
|
Histones | 1 | 2022 | 2570 | 0.020 |
Why?
|
Immunodominant Epitopes | 1 | 2013 | 237 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2016 | 961 | 0.020 |
Why?
|
Fever | 2 | 2012 | 1618 | 0.020 |
Why?
|
Safety | 1 | 2016 | 1151 | 0.020 |
Why?
|
Bangladesh | 1 | 2014 | 732 | 0.020 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2014 | 433 | 0.020 |
Why?
|
Recurrence | 2 | 2016 | 8457 | 0.020 |
Why?
|
Gene Expression | 2 | 2015 | 7571 | 0.020 |
Why?
|
Parasitemia | 1 | 2012 | 165 | 0.020 |
Why?
|
Antigens, Fungal | 1 | 2011 | 69 | 0.020 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2011 | 25 | 0.020 |
Why?
|
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2010 | 14 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2013 | 411 | 0.020 |
Why?
|
Urban Health | 1 | 2014 | 532 | 0.020 |
Why?
|
Poverty Areas | 1 | 2012 | 263 | 0.020 |
Why?
|
Immunity, Innate | 2 | 2015 | 3044 | 0.020 |
Why?
|
Intestinal Absorption | 1 | 2012 | 400 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2019 | 2329 | 0.020 |
Why?
|
Virus Integration | 1 | 2013 | 304 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2010 | 84 | 0.020 |
Why?
|
Motor Skills | 1 | 2014 | 521 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1567 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2010 | 95 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3688 | 0.020 |
Why?
|
Receptors, KIR | 1 | 2010 | 110 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 161 | 0.020 |
Why?
|
Education, Distance | 1 | 2014 | 260 | 0.020 |
Why?
|
Platelet Count | 1 | 2013 | 782 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2013 | 602 | 0.020 |
Why?
|
Iron Overload | 1 | 2012 | 239 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2018 | 1390 | 0.020 |
Why?
|
Child, Preschool | 4 | 2016 | 42224 | 0.020 |
Why?
|
Parity | 1 | 2013 | 929 | 0.020 |
Why?
|
Saliva | 1 | 2014 | 828 | 0.020 |
Why?
|
Brain | 1 | 2016 | 27092 | 0.020 |
Why?
|
Ferritins | 1 | 2012 | 596 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 2006 | 1702 | 0.020 |
Why?
|
Plasmodium | 1 | 2012 | 246 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2010 | 239 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2012 | 588 | 0.020 |
Why?
|
Meat | 1 | 2012 | 584 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20119 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3301 | 0.020 |
Why?
|
Cesarean Section | 1 | 2017 | 1399 | 0.020 |
Why?
|
Gene Frequency | 1 | 2015 | 3603 | 0.020 |
Why?
|
Nutrition Policy | 1 | 2012 | 466 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4567 | 0.020 |
Why?
|
Antigens, Viral | 1 | 2011 | 989 | 0.020 |
Why?
|
Creatinine | 1 | 2013 | 1897 | 0.020 |
Why?
|
Cell Count | 1 | 2011 | 1831 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3499 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2009 | 745 | 0.020 |
Why?
|
Delavirdine | 1 | 2006 | 7 | 0.020 |
Why?
|
Prenatal Diagnosis | 1 | 2014 | 1267 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2013 | 870 | 0.020 |
Why?
|
Military Personnel | 1 | 2015 | 1246 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2011 | 1140 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12052 | 0.020 |
Why?
|
Cell Separation | 1 | 2011 | 1721 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 672 | 0.020 |
Why?
|
HIV Fusion Inhibitors | 1 | 2005 | 82 | 0.020 |
Why?
|
Child | 4 | 2019 | 80152 | 0.020 |
Why?
|
Progesterone | 1 | 2009 | 742 | 0.020 |
Why?
|
Nevirapine | 1 | 2006 | 273 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3590 | 0.010 |
Why?
|
Sweating | 1 | 2005 | 155 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 7966 | 0.010 |
Why?
|
Receptors, Interleukin-7 | 1 | 2004 | 40 | 0.010 |
Why?
|
Demography | 1 | 2009 | 1641 | 0.010 |
Why?
|
Urban Population | 1 | 2013 | 2036 | 0.010 |
Why?
|
Energy Intake | 1 | 2012 | 2133 | 0.010 |
Why?
|
Injections, Intradermal | 1 | 2004 | 116 | 0.010 |
Why?
|
HIV Protease | 1 | 2004 | 97 | 0.010 |
Why?
|
Morbidity | 1 | 2009 | 1751 | 0.010 |
Why?
|
Perceptual Disorders | 1 | 2005 | 198 | 0.010 |
Why?
|
Erythrocytes | 1 | 2013 | 2413 | 0.010 |
Why?
|
Down-Regulation | 1 | 2010 | 2916 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2006 | 430 | 0.010 |
Why?
|
Influenza Vaccines | 1 | 2011 | 767 | 0.010 |
Why?
|
Leptin | 1 | 2011 | 1595 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3803 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2014 | 2923 | 0.010 |
Why?
|
Logistic Models | 2 | 2011 | 13249 | 0.010 |
Why?
|
Hepatitis C, Chronic | 1 | 2010 | 1027 | 0.010 |
Why?
|
Virus Activation | 1 | 2004 | 319 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6486 | 0.010 |
Why?
|
Chlamydia Infections | 1 | 2005 | 364 | 0.010 |
Why?
|
Body Weight | 1 | 2013 | 4618 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2011 | 1448 | 0.010 |
Why?
|
Point Mutation | 1 | 2007 | 1593 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2012 | 2189 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1472 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1385 | 0.010 |
Why?
|
Vaccines, Synthetic | 1 | 2004 | 612 | 0.010 |
Why?
|
Gonorrhea | 1 | 2005 | 346 | 0.010 |
Why?
|
Acetylation | 1 | 2004 | 1050 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2006 | 1518 | 0.010 |
Why?
|
Weight Gain | 1 | 2011 | 2349 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13402 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2009 | 1374 | 0.010 |
Why?
|
Osteonecrosis | 1 | 2003 | 228 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2009 | 6223 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9327 | 0.010 |
Why?
|
Organ Size | 1 | 2005 | 2253 | 0.010 |
Why?
|
Crohn Disease | 1 | 2013 | 2278 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2010 | 3210 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17598 | 0.010 |
Why?
|
Curriculum | 1 | 2014 | 3741 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
Biometry | 1 | 2003 | 563 | 0.010 |
Why?
|
Risk-Taking | 1 | 2006 | 1038 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2004 | 716 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 15920 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2014 | 4242 | 0.010 |
Why?
|
Body Composition | 1 | 2009 | 2427 | 0.010 |
Why?
|
HLA Antigens | 1 | 2004 | 1331 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2010 | 3821 | 0.010 |
Why?
|
Area Under Curve | 1 | 2002 | 1636 | 0.010 |
Why?
|
Imidazoles | 1 | 2004 | 1172 | 0.010 |
Why?
|
Research | 1 | 2007 | 1976 | 0.010 |
Why?
|
Pyrroles | 1 | 2004 | 1124 | 0.010 |
Why?
|
Blood Glucose | 1 | 2012 | 6392 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 2854 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2014 | 58952 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9416 | 0.010 |
Why?
|
Mass Screening | 1 | 2013 | 5426 | 0.010 |
Why?
|
Antioxidants | 1 | 2005 | 1667 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9616 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 2003 | 1936 | 0.010 |
Why?
|
Pilot Projects | 1 | 2010 | 8642 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 2928 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 5842 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2011 | 4413 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 16952 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7400 | 0.010 |
Why?
|
Radiography | 1 | 2003 | 6974 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15841 | 0.010 |
Why?
|
Ultrasonography | 1 | 2002 | 5969 | 0.010 |
Why?
|
Apoptosis | 1 | 2003 | 9477 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4872 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2002 | 20588 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 36415 | 0.000 |
Why?
|